Patient Capital Sees Royalty Pharma Valuation as Attractive
The strategy cited a 16.7-times multiple of 2027 owners’ earnings and forecast mid-teens earnings growth in most environments.
Key takeaways
- Patient Opportunity Equity Strategy said Royalty Pharma’s 16.7-times 2027 owners’ earnings multiple remained attractive.
- The strategy expects mid-teens earnings growth in most environments over the next few years.
Patient Opportunity Equity Strategy said Royalty Pharma’s 16.7-times multiple of 2027 owners’ earnings remains attractive, citing its view of the company’s risk-reward profile.
In its third-quarter investor letter, the strategy said Royalty Pharma had generated returns on capital in the high teens and forecast mid-teens earnings growth in most environments over the next few years. Those figures and projections reflect the strategy’s assessment.
Royalty Pharma shares traded at $57.19 at 15:38 UTC on Oct. 12, up 0.45% from the previous close, according to live market data.
This article was produced with the help of AI technology. Source: Yahoo Finance
